Market Overview:
The global cardiometabolic drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cardiometabolic disorders, rising geriatric population, and technological advancements in the field of cardiology. Based on type, the global cardiometabolic drug market is segmented into impaired glucose tolerance drugs, insulin resistance drugs, hypertension drugs, dyslipidemia drugs, and central adiposity drugs. The impaired glucose tolerance drug segment is expected to account for the largest share of the global cardiometabolic drug market in 2018. This segment is projected to grow at a CAGR of 8% during the forecast period from 2018 to 2030. This growth can be attributed to increasing awareness about diabetes mellitus and its complications among people across the globe. Based on application,the global cardiometabolic drug market is divided into hospital pharmacies, online pharmacies,, and retail pharmacies segments. The hospital pharmacies segment accounted for majority share (64%)of th eglobalcardiom etaboli cdrugmarketin2018 .
Product Definition:
A cardiometabolic drug is a medication that helps to treat conditions related to the heart and blood vessels, such as high blood pressure and diabetes. These drugs can help to improve patient outcomes by lowering cholesterol levels, controlling blood sugar levels, and preventing heart disease.
Impaired Glucose Tolerance Drug:
Impaired glucose tolerance (IGT) is a condition where the body cannot metabolize sugar properly. The two types of IGT are latent and apparent. Latent IGT is when there are no symptoms of the disease, while apparent IGT has certain symptoms such as frequent urination, fatigue, headache and drowsiness.
U.S Impaired Glucose Tolerance Market by Type (LAT & AP), 2018 - 2025 -> The U.
Insulin Resistance Drug:
Insulin resistance is a condition in which the body does not produce enough insulin to enable cells to uptake glucose (sugar) from the blood. The most common symptoms of insulin resistance are weight gain, fatigue, and frequent urination. In addition, some other symptoms include muscle pain or ache, cold intolerance, headache and dizziness among others.
Application Insights:
The global cardiometabolic drug market is segmented by application into hospital pharmacies, online pharmacies and retail pharmacies. The hospital pharmacy segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as presence of a large patient base with various chronic diseases associated with obesity and diabetes, high prevalence of Cardiovascular Diseases (CVDs) and rising geriatric population across the globe.
The online pharmacy segment is expected to grow at a lucrative rate over the forecast period owing to increasing internet usage rates coupled with growing awareness about adopting new technology for healthcare delivery among consumers worldwide.
Regional Analysis:
North America dominated the global market in 2017. Key factors contributing to its growth include favorable government initiatives, increasing prevalence of obesity and diabetes, and rising awareness about early diagnosis. For instance, as per the American Diabetes Association’s 2015 statistics, around 39 million people were living with diabetes in U.S., which is an increase of 6% compared to 2010 estimates.
Asia Pacific is expected to be one of the fastest-growing regions during the forecast period owing to a large population base suffering from cardiometabolic disorders coupled with improving healthcare infrastructure and economic development especially in India & China. Moreover it has been observed that these diseases are more prevalent among Asian populations than white populations (3).
Growth Factors:
- Increasing prevalence of obesity and diabetes: The global prevalence of obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults were overweight, of which 600 million were obese. The number of people with diabetes has also increased from 108 million in 1980 to 422 million in 20142. Rising awareness about the health risks associated with cardiometabolic diseases: There is a growing awareness among people about the health risks associated with cardiometabolic diseases such as obesity, type 2 diabetes, heart disease and stroke3. Growing demand for novel therapies: Cardiometabolic diseases are often chronic and progressive conditions that require long-term treatment plans. This is driving the demand for novel therapies4. Technological advancements: Advances in technology are helping to improve our understanding of cardiometabolic diseases and develop new treatments5 Increased funding for research and development: There is increasing funding for research and development into new drugs to treat cardiometabolic diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Cardiometabolic Drug Market Research Report
By Type
Impaired Glucose Tolerance Drug, Insulin Resistance Drug, Hypertension Drug, Dyslipidemia Drug, Central Adiposity Drug
By Application
Hospital Pharmacies, Online Pharnacies, Retail Pharmacies
By Companies
Gilead Sciences, AbbVie, Sanofi, InovoBiologic, Carmel Biosciences, Genfit, Kochi Prefecture, Besins Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Cardiometabolic Drug Market Report Segments:
The global Cardiometabolic Drug market is segmented on the basis of:
Types
Impaired Glucose Tolerance Drug, Insulin Resistance Drug, Hypertension Drug, Dyslipidemia Drug, Central Adiposity Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Online Pharnacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- AbbVie
- Sanofi
- InovoBiologic
- Carmel Biosciences
- Genfit
- Kochi Prefecture
- Besins Healthcare
Highlights of The Cardiometabolic Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Impaired Glucose Tolerance Drug
- Insulin Resistance Drug
- Hypertension Drug
- Dyslipidemia Drug
- Central Adiposity Drug
- By Application:
- Hospital Pharmacies
- Online Pharnacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cardiometabolic Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cardiometabolic drugs are medications that help to improve the overall heart health of a person. These drugs can work to lower blood pressure, cholesterol levels, and triglyceride levels. They may also help to prevent or reduce the risk of heart disease.
Some of the major players in the cardiometabolic drug market are Gilead Sciences, AbbVie, Sanofi, InovoBiologic, Carmel Biosciences, Genfit, Kochi Prefecture, Besins Healthcare.
The cardiometabolic drug market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cardiometabolic Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cardiometabolic Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cardiometabolic Drug Market - Supply Chain
4.5. Global Cardiometabolic Drug Market Forecast
4.5.1. Cardiometabolic Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cardiometabolic Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cardiometabolic Drug Market Absolute $ Opportunity
5. Global Cardiometabolic Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cardiometabolic Drug Market Size and Volume Forecast by Type
5.3.1. Impaired Glucose Tolerance Drug
5.3.2. Insulin Resistance Drug
5.3.3. Hypertension Drug
5.3.4. Dyslipidemia Drug
5.3.5. Central Adiposity Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cardiometabolic Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cardiometabolic Drug Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Online Pharnacies
6.3.3. Retail Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cardiometabolic Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cardiometabolic Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cardiometabolic Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cardiometabolic Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cardiometabolic Drug Demand Share Forecast, 2019-2026
9. North America Cardiometabolic Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cardiometabolic Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cardiometabolic Drug Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Online Pharnacies
9.4.3. Retail Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cardiometabolic Drug Market Size and Volume Forecast by Type
9.7.1. Impaired Glucose Tolerance Drug
9.7.2. Insulin Resistance Drug
9.7.3. Hypertension Drug
9.7.4. Dyslipidemia Drug
9.7.5. Central Adiposity Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cardiometabolic Drug Demand Share Forecast, 2019-2026
10. Latin America Cardiometabolic Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cardiometabolic Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cardiometabolic Drug Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Online Pharnacies
10.4.3. Retail Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cardiometabolic Drug Market Size and Volume Forecast by Type
10.7.1. Impaired Glucose Tolerance Drug
10.7.2. Insulin Resistance Drug
10.7.3. Hypertension Drug
10.7.4. Dyslipidemia Drug
10.7.5. Central Adiposity Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cardiometabolic Drug Demand Share Forecast, 2019-2026
11. Europe Cardiometabolic Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cardiometabolic Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cardiometabolic Drug Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Online Pharnacies
11.4.3. Retail Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cardiometabolic Drug Market Size and Volume Forecast by Type
11.7.1. Impaired Glucose Tolerance Drug
11.7.2. Insulin Resistance Drug
11.7.3. Hypertension Drug
11.7.4. Dyslipidemia rug
11.7.5. Central Adiposity Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cardiometabolic Drug Demand Share, 2019-2026
12. Asia Pacific Cardiometabolic Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cardiometabolic Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cardiometabolic Drug Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Online Pharnacies
12.4.3. Retail Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cardiometabolic Drug Market Size and Volume Forecast by Type
12.7.1. Impaired Glucose Tolerance Drug
12.7.2. Insulin Resistance Drug
12.7.3. Hypertension Drug
12.7.4. Dyslipidemia Drug
12.7.5. Central Adiposity Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cardiometabolic Drug Demand Share, 2019-2026
13. Middle East & Africa Cardiometabolic Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cardiometabolic Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cardiometabolic Drug Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Online Pharnacies
13.4.3. Retail Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cardiometabolic Drug Market Size and Volume Forecast by Type
13.7.1. Impaired Glucose Tolerance Drug
13.7.2. Insulin Resistance Drug
13.7.3. Hypertension Drug
13.7.4. Dyslipidemia Drug
13.7.5. Central Adiposity Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cardiometabolic Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Cardiometabolic Drug Market: Market Share Analysis
14.2. Cardiometabolic Drug Distributors and Customers
14.3. Cardiometabolic Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gilead Sciences
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AbbVie
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. InovoBiologic
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Carmel Biosciences
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Genfit
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Kochi Prefecture
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Besins Healthcare
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
